Skip to contentR
Royalty Pharma plc
R
RPRXRoyalty Pharma plc Q2 2026 · 10-Q
Revenue$674.14M$674.14M+16.5% vs Q2 2025 Net Income$17.88M$17.88M−44.4% vs Q2 2025 EPS Diluted$0.04$0.04−42.9% vs Q2 2025 Operating Income$133,119,000−36.5% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Royalty Pharma plc · CIK 1802768 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin19.7%−16.5 pt vs Q2 2025
Net margin2.7%−2.9 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 5, 2026 · 36 d after period end